DNA Methylation and Intra-Clonal Heterogeneity: The Chronic Myeloid Leukemia Model
| Autor: | Céline Bourgne, Benjamin Lebecque, Marc G. Berger, Véronique Vidal |
|---|---|
| Přispěvatelé: | Role of intra-Clonal Heterogeneity and Leukemic environment in ThErapy Resistance of chronic leukemias (CHELTER), Université Clermont Auvergne (UCA) |
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
Cancer Research Review Biology 03 medical and health sciences 0302 clinical medicine chronic myeloid leukemia hemic and lymphatic diseases Epigenetics RC254-282 DNA methylation business.industry Disease progression Myeloid leukemia Neoplasms. Tumors. Oncology. Including cancer and carcinogens [SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology Methylation clonal heterogeneity Fusion protein 3. Good health 030104 developmental biology Oncology 030220 oncology & carcinogenesis Cancer research Personalized medicine business Tyrosine kinase |
| Zdroj: | Cancers, Vol 13, Iss 3587, p 3587 (2021) Cancers Cancers, MDPI, 2021, 13 (14), pp.3587. ⟨10.3390/cancers13143587⟩ |
| ISSN: | 2072-6694 |
| Popis: | Simple Summary In Chronic Myeloid Leukemia (CML), intra-clonal heterogeneity is a major factor in the response to tyrosine kinase inhibitors and in leukemia stem cell persistence. This intra-clonal heterogeneity could be partially explained by epigenetic abnormalities. This review focuses on DNA methylation abnormalities in CML and its potential implications for the development of new biomarkers of the treatment response and new therapy opportunities. DNA methylation abnormalities are considered an important event in the CML progression phase. Moreover, in recent years, DNA methylation abnormalities have also been characterized at CML diagnosis (in the chronic phase), with specific alterations in the immature cells of the tumor clone. Lastly, the review discusses the importance of these finding for understanding the disease emergence, for developing new therapeutic strategies, and for a personalized management of CML. Abstract Chronic Myeloid Leukemia (CML) is a model to investigate the impact of tumor intra-clonal heterogeneity in personalized medicine. Indeed, tyrosine kinase inhibitors (TKIs) target the BCR-ABL fusion protein, which is considered the major CML driver. TKI use has highlighted the existence of intra-clonal heterogeneity, as indicated by the persistence of a minority subclone for several years despite the presence of the target fusion protein in all cells. Epigenetic modifications could partly explain this heterogeneity. This review summarizes the results of DNA methylation studies in CML. Next-generation sequencing technologies allowed for moving from single-gene to genome-wide analyses showing that methylation abnormalities are much more widespread in CML cells. These data showed that global hypomethylation is associated with hypermethylation of specific sites already at diagnosis in the early phase of CML. The BCR-ABL-independence of some methylation profile alterations and the recent demonstration of the initial intra-clonal DNA methylation heterogeneity suggests that some DNA methylation alterations may be biomarkers of TKI sensitivity/resistance and of disease progression risk. These results also open perspectives for understanding the epigenetic/genetic background of CML predisposition and for developing new therapeutic strategies. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|